Clinical trials: Klebsiella Pneumoniae Infection
Carbapenemase-producing Enterobacteriaceae Infection
Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae
Infections caused by carbapenemase-producing Enterobacteriaceae are frequent and often associated with high rates of mortality. Colonized patients are at increased risk of infection for these microorganisms.
- Trial name
- KAPEDIS (NCT04760665)
- Testing
- Fecal microbiota transplantation
- Where
- Spain
- Volunteers
- 2 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).
Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3).
- Trial name
- NCT01266499
- Testing
- Colistin (Polymyxin E) 100mg x 4/d, both medications, will not receive PO treatment
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Bloodstream Infection
Comparison of Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae
COMBAT trial was contemplated to elucidate unknown clinical relevance of carbapenem heteroresistance among Klebsiella pneumoniae species.
- Trial name
- COMBAT (NCT04229498)
- Testing
- Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- SCARE (Study group for carbapenem resistance)
Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae
Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae
This prospective, comparative study is evaluating the effectiveness and adverse effects of using colistin at a loading dose of 9 million international units (MIU) followed by 4.5 MIU every 12 h (q12 h) + tigecycline at a loading…
- Trial name
- NCT04489459
- Testing
- Colistin, Meropenem, Tigecycline
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Carbapenemase-Producing Enterobacteriaceae
Incidence and Risk Factors for Developing Infections in Patients Colonized by CP-KPC
The worldwide increase in the rate of infections due to multidrug-resistant bacteria is considered a major public health problem.
- Trial name
- KPC (NCT05492539)
- Where
- Argentina
- Volunteers
- 500 people
- Sponsor
- Hospital Italiano de Buenos Aires
Escherichia Coli Infections, Klebsiella Pneumonia
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
There has been a great increase in the incidence of infections caused by bacteria that are resistant to antibiotic agents. Many of these infections result in worse outcomes of patients and increased costs to the healthcare…
- Trial name
- NCT01324726
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- American University of Beirut Medical Center
Wound Infection
Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients
The central aim of this trial is to investigate the safety and tolerability of Phage Cocktail-SPK as an adjunct to standard therapy for the prevention and treatment of burns susceptible to infection/or infected by S. aureus, P.
- Trial name
- NCT04323475
- Testing
- Bacteriophage cocktail spray, Xeroform
- Volunteers
- 12 people
- Sponsor
- Precisio Biotix Therapeutics, Inc.
High-dose Biapenem
Clinical Efficacy of Combination Therapy Based on High-dose Biapenem in CRKP Infections
Carbapenem resistance is a high mortality rate of Klebsiella pneumoniae infection. It has been proved that high-dose carbapenem can reduce mortality and has a certain clinical effect.
- Trial name
- NCT04552444
- Testing
- Biapenem
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Klebsiella Pneumoniae Infection
WGS-guided Tracking and Infection Control Measures of CRKP
The objective of this study is to investigate the effect of the infection control measures based on the active screening of carbapenem-resistant Klebsiella pneumoniae and whole-genome based tracking and surveillance though the…
- Trial name
- NCT04413305
- Testing
- screen of CRKP and infection control measure
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Huashan Hospital
Klebsiella Pneumoniae Infection
Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)
In this study, the tetravalent bioconjugate candidate vaccine Kleb4V will be tested to obtain first-time-in-human (FTIH) data on its safety and immunogenicity in healthy adults.
- Trial name
- NCT04959344
- Testing
- Kleb4V target dose, Kleb4V target dose + AS03, Kleb4V low dose
- Where
- 2 sites in Germany
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Longitudinal, Genomic Stability
Epidemiology and Overtime Genomic Evolution of Klebsiella Pneumoniae and Enterobacter Cloacae Complex (ECC) in Stools of ICU's Patients
Infections are one of the major threats for inpatients, even more for patients hospitalized in intensive care units (ICUs). They are responsible for an important increase of morbidity and mortality rates as well as a burst of…
- Conditions
- Longitudinal, Genomic Stability, Klebsiella Infections, Enterobacter Cloacae Infection
- Trial name
- NormandyKlebs (NCT07744321)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Caen
Severe Infection
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients
Ceftazidime/avibactam (CZA) is an essential treatment option for managing infections caused by multidrug-resistant (MDR) gram-negative (G-) bacteria, including Klebsiella pneumoniae OXA-48 and carbapenem-resistant Pseudomonas…
- Trial name
- ZAVICONT (NCT06811727)
- Testing
- Continuos ceftazidime/avibactam infusion, Intermitent dosing as per SMPC
- Where
- Croatia
- Volunteers
- 140 people
- Sponsor
- Ivan Šitum, MD
Infections
Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli
In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.
- Trial name
- NCT00300560
- Testing
- Colistin
- Where
- Thailand
- Volunteers
- 152 people
- Sponsor
- Mahidol University
Liver Abscess, Pyogenic
Antibiotics for Klebsiella Liver Abscess Study
Background: Klebsiella pneumoniae liver abscess is the most common etiology of liver abscess in Singapore and much of Asia, and its incidence is increasing.
- Trial name
- NCT01723150
- Testing
- Ciprofloxacin, Ceftriaxone, Trimethoprim/sulfamethoxazole
- Where
- 3 sites in Singapore
- Volunteers
- 152 people
- Sponsor
- National University Hospital, Singapore
Klebsiella Pneumoniae Infection, Vaccine
An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults
CHO-V08 is currently being developed as a prevention vaccine against nosocomial and community-acquired infection caused by hypervirulent Klebsiella pneumoniae K1 and K2 serotypes.
- Trial name
- NCT07016152
- Testing
- Glyconjugate Klebsiella pneumoniae bivalent vaccine
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cho Pharma Inc.
Gram-negative Bacteremia
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of…
- Trial name
- GOAT (NCT06080698)
- Testing
- Intravenous Antibiotics, Oral Antibiotics
- Where
- 11 sites in United States
- Volunteers
- 1,030 people
- Sponsor
- Johns Hopkins University
Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae
Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli
In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E.
- Trial name
- E-Trike (NCT07106944)
- Testing
- Community pregnant women: rectal and throat swab
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Escherichia Coli Infections, Klebsiella Infections
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care…
- Trial name
- NCT00167986
- Testing
- vancomycin-resistant enterococci and ESBL
- Where
- South Korea
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Liver Abscess, Pyogenic
Pyogenic Liver Abcess in Guadeloupe
Liver abscesses are infections of the liver parenchyma, most often bacterial, occurring via the biliary tract, bloodstream, or by direct spread. Although rare, they are serious, with a mortality rate of around 15%.
- Trial name
- PYG (NCT07579104)
- Where
- Guadeloupe
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Hematologic Neoplasms, Gram-Negative Bacterial Infections
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
This is a prospective, single-arm, observational, exploratory clinical study to evaluate whether the standard fixed dose of ceftazidime-avibactam (CAZ-AVI) achieves sufficient drug exposure (pharmacokinetic/pharmacodynamic, or…
- Conditions
- Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
- Trial name
- CZA-TDM (NCT07703644)
- Testing
- Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sizhou Feng